Bibliography
- Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8
- McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3(10):737-47
- Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296(5567):550-3
- Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007;8(3):173-84
- Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA 2005;11(12):1753-61
- Lingor P, Bahr M. Targeting neurological disease with RNAi. Mol Biosyst 2007;3(11):773-80
- Ralph GS, Mazarakis ND, Azzouz M. Therapeutic gene silencing in neurological disorders, using interfering RNA. J Mol Med 2005;83(6):413-9
- Pardridge WM. shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev 2007;59(2-3):141-52
- Mathupala SP, Guthikonda M, Sloan AE. RNAi based approaches to the treatment of malignant glioma. Technol Cancer Res Treat 2006;5(3):261-9
- Mathupala SP, Mittal S, Guthikonda M, Sloan AE. MicroRNA and brain tumors: a cause and a cure? DNA Cell Biol 2007;26(5):301-10
- Zukiel R, Nowak S, Wyszko E, et al. Suppression of human brain tumor with interference RNA specific for tenascin-C. Cancer Biol Ther 2006;5(8):1002-7
- Pardridge WM. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther 2004;4(7):1103-13
- Xia CF, Zhang Y, Boado RJ, Pardridge WM. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 2007;24(12):2309-16
- Zhang Y, Boado RJ, Pardridge WM. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med 2003;5(12):1039-45
- Zhang Y, Zhang YF, Bryant J, et al. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004;10(11):3667-77
- Meade BR, Dowdy SF. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 2007;59(2-3):134-40
- Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007;117(12):3623-32
- Ferguson S, Lesniak MS. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr Drug Deliv 2007;4(2):169-80
- Ferguson SD, Foster K, Yamini B. Convection-enhanced delivery for treatment of brain tumors. Expert Rev Anticancer Ther 2007;7(12 Suppl):S79-85
- Zhang Y, Zhang YF, Bryant J, et al. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004;10(11):3667-77
- Boado RJ. RNA interference and nonviral targeted gene therapy of experimental brain cancer. NeuroRx 2005;2(1):139-50
- Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007;448(7149):39-43
- Jain KK. Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Rev Neurother 2007;7(4):363-72
- Lesniak MS. Novel advances in drug delivery to brain cancer. Technol Cancer Res Treat 2005;4(4):417-28
- Campbell M, Kiang AS, Kenna PF, et al. RNAi-mediated reversible opening of the blood-brain barrier. J Gene Med 2008;10(8):930-47
- Davidson TJ, Harel S, Arboleda VA, et al. Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci 2004;24(45):10040-6
- Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 2004;558(1-3):63-8
- Chiu YL, Ali A, Chu CY, et al. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004;11(8):1165-75
- Rousselle C, Clair P, Lefauconnier JM, et al. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000;57(4):679-86